• MacroGenics reported interim Phase 2 LINNET results showing lorigerlimab achieved a 25% confirmed response rate in advanced clear cell gynecologic cancer.
• Disease control reached 44% among 16 response-evaluable patients; all responses remained ongoing at the Sept. 1, 2026, cutoff.
• Grade 3 or higher treatment-related adverse events affected 49% of 41 patients across both cancer cohorts; one treatment-related death occurred.
• Treatment-related adverse events led to discontinuation in 24% of patients overall, versus 18% in the clear cell gynecologic cancer cohort.
• Additional clear cell gynecologic cancer patients are receiving 3 mg/kg every three weeks, with updated results expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260706PRIMZONEFULLFEED9852910) on October 26, 2026, and is solely responsible for the information contained therein.